Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

How a Pharma Company Managed a Single-Source API Supplier Exit Under ICH M7

Pharmaceutical supply chains face growing pressure from global sourcing, geopolitical risks, product availability issues, and stricter regulatory expectations. Therefore, companies must manage supplier changes with greater control and scientific rigor.

However, many organizations underestimate the risks of a MonoSource Exit Program, especially when they must integrate supplier qualification with ICH M7 lifecycle management for mutagenic impurities.

A supplier exit may appear simple: select an alternative supplier and qualify it. In practice, the company must collect technical documentation, evaluate impurity risks, assign responsibilities, decide whether additional testing is necessary, and document every decision.

Without a structured MSEP, projects can stall and regulatory gaps can emerge. Moreover, incomplete impurity assessments may expose the company to CAPAs, inspection findings, supply disruption, or product recalls.

In this case, an Operational Project Manager created a two-stage MSEP process. The process connected supplier documentation review with ICH M7 toxicological assessment, impurity control, batch qualification, and traceable decision-making.

Our team structured the supplier entry process, defined documentation and tracking requirements, coordinated expert reviews, and connected supplier qualification decisions with mutagenic and nitrosamine impurity assessments.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Incomplete Supplier Documentation: Scientific review required technical packages, process details, impurity profiles, CoAs, validation data, and mutagenic or nitrosamine information.
  • Weak Decision Traceability: Without controlled trackers, the company could not clearly link data gaps to testing, expert reviews, or qualification decisions.
  • Unclear Roles and Responsibilities: The process required clear RACI ownership across toxicology, Quality, Regulatory Affairs, and other experts.
  • Mutagenic Impurity Risk: The company needed ICH M7 assessments, Acceptable Limits, control categories, and decisions on Ames or further toxicology testing.
  • Nitrosamine Assessment Requirements: Supplier files also had to address nitrosamine risks and show how they affected testing and qualification.
  • Batch Qualification Alignment: Representative supplier batches had to meet impurity, quality, and toxicology expectations before qualification.
  • Risk of Regulatory Findings: A 2023 FDA observation showed that undocumented links between supplier gaps and testing strategies create inspection risk.

Zamann Pharma Support’s Approach

  • Two-Stage MSEP Structure: The manager divided MSEP into supplier documentation review and ICH M7 toxicological assessment.
  • Supplier Documentation Gateway: The team defined required technical, process, validation, CoA, mutagenic, and nitrosamine documents.
  • Centralized Tracking System: Central trackers and controlled memos recorded submissions, gaps, reviews, decisions, and outcomes.
  • Expert Review Framework: Toxicology, Quality, and Regulatory experts reviewed supplier data under clear RACI responsibilities.
  • Supplier GAP Assessment: Reviewers identified missing documents, open impurity questions, and additional testing needs.
  • Formal Expert Memo: Process 1 ended with a signed memo that transferred documented conclusions into Process 2.
  • ICH M7 Toxicological Assessment: Toxicologists evaluated identified mutagenic impurities under ICH M7.
  • Acceptable Limit Assessment: The team established Acceptable Limits to support impurity control and qualification.
  • Control Category Assignment: Experts assigned each impurity to the relevant ICH M7 category.
  • Testing Strategy Development: The team decided whether qualification required Ames testing or further toxicology studies.
  • Batch Qualification Support: Representative supplier lots were assessed against impurity, quality, and toxicology expectations.

Results Achieved

  • Structured MSEP Process Established: The case created a clear two-stage process that connected supplier documentation review with ICH M7 toxicological assessment.
  • Supplier Documentation Standardized: Process 1 defined the technical, quality, validation, and impurity information required before supplier evaluation could proceed.
  • Decision Traceability Improved: Central trackers and version-controlled records linked supplier submissions, identified GAPs, expert reviews, and final decisions.
  • Formal Expert Memo Produced: The expert team prepared a signed and archived memo that documented the outcome of Process 1 and supported the transition into Process 2.
  • Roles and Responsibilities Clarified: The expert review framework assigned responsibilities across toxicology, Quality, Regulatory Affairs, and other relevant functions.
  • ICH M7 Assessment Integrated: Process 2 connected Acceptable Limit assessments, impurity categorization, toxicological testing decisions, and batch qualification.
  • Impurity Risks Linked to Qualification: The process connected mutagenic and nitrosamine impurity findings with testing requirements and supplier qualification outcomes.
  • Key Strategic Priorities Defined: The case identified three central requirements: structured documentation, early toxicology involvement, and complete decision tracking.
Laboratory
Pharmaceutical quality team reviewing nitrosamines risk assessment documentation aligned with ICH M7 and current regulatory compliance requirements
Services

Nitrosamines Regulatory Compliance

We assist pharmaceutical teams in assessing and managing nitrosamines risks by aligning processes with ICH M7 requirements and current regulatory expectations.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. What supplier documents should a MonoSource Exit Program collect before ICH M7 review?

The initial package should include process descriptions, technical documentation, impurity profiles, Certificates of Analysis, validation data, and information about potential mutagenic or nitrosamine impurities.

 

The company should use a centralized tracker and a signed, version-controlled expert memo that connects each documentation GAP with the selected testing strategy and final qualification decision.

3. When should toxicologists join an alternative-supplier qualification project?

Toxicologists should participate during the initial supplier-documentation and GAP review. Early involvement helps identify mutagenic impurity risks before late-stage testing or batch qualification creates delays.